Bioxytran, Inc. (BIXT)
USD 0.13
(-15.4%)
USD 0.13
(-15.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -8285.00 USD | -127.36% |
| 2022 | -3644.00 USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 87.09 Thousand USD | -42.01% |
| 2016 | 150.19 Thousand USD | 25.02% |
| 2015 | 120.13 Thousand USD | 9.58% |
| 2014 | 109.63 Thousand USD | -50.15% |
| 2013 | 219.94 Thousand USD | 15.16% |
| 2012 | 190.98 Thousand USD | 233.77% |
| 2011 | 57.22 Thousand USD | 372.98% |
| 2010 | 12.09 Thousand USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 27.83 Thousand USD | 122.81% |
| 2024 Q3 | -1516.00 USD | 1.3% |
| 2024 Q2 | -1536.00 USD | -105.52% |
| 2023 Q2 | - USD | -100.0% |
| 2023 Q3 | 50.5 Thousand USD | 0.0% |
| 2023 Q4 | -122.01 Thousand USD | -341.6% |
| 2023 FY | -8285.00 USD | -127.36% |
| 2023 Q1 | 67.22 Thousand USD | 1944.7% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2022 FY | -3644.00 USD | 0.0% |
| 2022 Q4 | -3644.00 USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q3 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2021 Q2 | - USD | 0.0% |
| 2020 Q3 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q1 | - USD | 100.0% |
| 2019 Q3 | - USD | 0.0% |
| 2018 Q2 | 12.19 Thousand USD | 730.88% |
| 2018 Q4 | -56.99 Thousand USD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2018 Q1 | -1933.00 USD | 71.7% |
| 2018 Q3 | - USD | -100.0% |
| 2017 Q3 | 80.09 Thousand USD | 298.93% |
| 2017 FY | 87.09 Thousand USD | -42.01% |
| 2017 Q1 | -6237.00 USD | -117.46% |
| 2017 Q4 | -6831.00 USD | -108.53% |
| 2017 Q2 | 20.07 Thousand USD | 421.89% |
| 2016 FY | 150.19 Thousand USD | 25.02% |
| 2016 Q4 | 35.73 Thousand USD | -43.23% |
| 2016 Q1 | 14.71 Thousand USD | 406.52% |
| 2016 Q3 | 62.94 Thousand USD | 71.03% |
| 2016 Q2 | 36.8 Thousand USD | 150.02% |
| 2015 FY | 120.13 Thousand USD | 9.58% |
| 2015 Q1 | 47.94 Thousand USD | 161.82% |
| 2015 Q2 | 44.67 Thousand USD | -6.81% |
| 2015 Q3 | 42.98 Thousand USD | -3.78% |
| 2015 Q4 | -4802.00 USD | -111.17% |
| 2014 Q2 | 25.84 Thousand USD | -83.24% |
| 2014 Q3 | 7189.00 USD | -72.18% |
| 2014 FY | 109.63 Thousand USD | -50.15% |
| 2014 Q4 | -77.55 Thousand USD | -1178.75% |
| 2014 Q1 | 154.15 Thousand USD | 122.81% |
| 2013 Q4 | 69.18 Thousand USD | 376.77% |
| 2013 FY | 219.94 Thousand USD | 15.16% |
| 2013 Q1 | 103.91 Thousand USD | 208.03% |
| 2013 Q2 | 55.27 Thousand USD | -46.8% |
| 2013 Q3 | 14.51 Thousand USD | -73.75% |
| 2012 Q1 | 98.69 Thousand USD | 470.18% |
| 2012 Q2 | 83.91 Thousand USD | -14.97% |
| 2012 Q4 | 33.73 Thousand USD | 233.04% |
| 2012 Q3 | -25.35 Thousand USD | -130.22% |
| 2012 FY | 190.98 Thousand USD | 233.77% |
| 2011 Q4 | 17.3 Thousand USD | 74.86% |
| 2011 FY | 57.22 Thousand USD | 372.98% |
| 2011 Q2 | 24.06 Thousand USD | 304.59% |
| 2011 Q1 | 5948.00 USD | 55.38% |
| 2011 Q3 | 9899.00 USD | -58.87% |
| 2010 Q4 | 3828.00 USD | 185.25% |
| 2010 FY | 12.09 Thousand USD | 0.0% |
| 2010 Q2 | 4858.00 USD | 134.91% |
| 2010 Q1 | 2068.00 USD | 0.0% |
| 2010 Q3 | 1342.00 USD | -72.38% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 100.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | -36.37 Thousand USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -239.688% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 100.071% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 97.407% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.007% |
| Qrons Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.968% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 82.832% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 93.332% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.055% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 367.086% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 100.085% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 112.605% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 75.739% |
| Mesoblast Limited | -35.16 Million USD | 99.976% |
| Marizyme, Inc. | 457.7 Thousand USD | 101.81% |
| Genus plc | 178.7 Million USD | 100.005% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.004% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 113.314% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 102.02% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 24.682% |
| ContraFect Corporation | -154 Thousand USD | 94.62% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 83.43% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 110.793% |
| IMV Inc. | -962.29 Thousand USD | 99.139% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 97.862% |
| MultiCell Technologies, Inc. | 49.32 USD | 16898.459% |
| ONE Bio Corp. | 20.12 Million USD | 100.041% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.021% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 116.943% |
| Q BioMed Inc. | -8988.00 USD | 7.822% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.029% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 46.285% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.019% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 99.274% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 111.836% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -67.306% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 105.897% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 91.504% |
| GB Sciences, Inc. | -624.00 USD | -1227.724% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 90.369% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -3883.173% |
| Enzolytics Inc. | 30.7 Thousand USD | 126.98% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 101.717% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.001% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 98.39% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 101.342% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.002% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 6.448% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 90.119% |
| Kadimastem Ltd | -630.13 Thousand USD | 98.685% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 100.839% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 100.086% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.054% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 29.996% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 104.692% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 104.692% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 100.61% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 71.431% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 101.841% |
| SYBLEU INC | 11.69 Thousand USD | 170.836% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 100.18% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 97.779% |
| Neutra Corp. | 14.33 Thousand USD | 157.796% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 89.896% |
| PureTech Health plc | -1.6 Million USD | 99.483% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 99.173% |
| IXICO plc | 3.27 Million USD | 100.253% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 98.806% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 99.537% |
| CSL Limited | 7.7 Billion USD | 100.0% |
| Cellectis S.A. | 18 Thousand USD | 146.028% |